ApoB: the cardiovascular marker your lipid panel missed

Why particle count predicts events better than cholesterol content — and what to request instead.

A 48-year-old managing partner — let’s call him Adam — sat across from me holding his executive health report. Clean bill of health, his cardiologist had written. LDL cholesterol at 2.7 mmol/L (104 mg/dL) — well within guidelines. Coronary calcium score of zero. By every standard metric, Adam was cardiovascular-clear.

His apolipoprotein B was 1.2 g/L (120 mg/dL). Guidelines call that normal. Normal is not the same as safe — and it is nowhere near optimal. I will tell you what optimal looks like at the end.

Standard lipid panels were designed in the 1970s to detect existing cardiovascular disease. They measure cholesterol content — how much cholesterol is packed inside lipoprotein particles. They do not count the particles themselves. This distinction matters far less when you are managing established pathology. It matters enormously when you are optimising for 30 more years of high-output performance.

Each LDL particle, regardless of its cholesterol content, carries exactly one apolipoprotein B molecule on its surface. ApoB is therefore a direct count of atherogenic particle number — how many particles capable of penetrating your arterial wall are circulating at any given time.

Particle number drives cardiovascular risk. Cholesterol content is secondary.

The Copenhagen General Population Study followed over 13,000 statin-treated patients and found that apoB predicted major adverse cardiovascular events and all-cause mortality significantly better than LDL cholesterol. The CARDIA study tracked young adults for 25 years and found those with high apoB but normal LDL-C had 55% higher risk of developing coronary artery calcification. The reverse — high LDL-C but normal apoB — showed no increased risk.

This discordance happens because particle size varies dramatically between individuals. Some people carry their cholesterol in a few large, buoyant LDL particles. Others distribute it across many small, dense ones. A standard panel sees the same cholesterol content and calls both patients equivalent. They are not.

Sources: Mortensen et al., JACC — Copenhagen General Population Study; Wilkins et al., JACC — CARDIA 25-year follow-up on ApoB-LDL discordance and coronary artery calcification.

Small, dense LDL particles penetrate arterial walls more easily. They circulate longer. They oxidise faster. A patient with textbook LDL cholesterol but high particle count is running the phenotype that drives events — and their standard panel will never flag it.

Adam’s advanced panel confirmed exactly this. His particle distribution was predominantly small and dense. His oxidised LDL was elevated at 48 U/L (reference <34 U/L). His lipoprotein(a) came back at 180 nmol/L (75 mg/dL) — a genetically determined, independent risk amplifier that standard panels do not measure — adding a second layer of concern. His cardiologist had been measuring cargo. We needed to count vehicles.

For someone planning to sustain executive-level performance for decades, optimal apoB sits below 0.8 g/L (80 mg/dL) — not the population reference range of under 1.2 g/L (120 mg/dL). In my practice, I aim lower still: below 0.5 g/L (50 mg/dL). That threshold reflects the level at which cumulative atherogenic particle exposure over 30 years becomes negligible rather than compounding. Most executive health panels will not flag anything until you are well past that number.

The intervention targeted particle number through two levers: clearance and size. Particle size responds to dietary saturated fat reduction and omega-3 optimisation more reliably than cholesterol content does. Particle clearance improves with hepatic insulin sensitivity — a variable that compounds across both cardiovascular and metabolic longevity.

At three months, Adam’s apoB had dropped to 0.82 g/L (82 mg/dL). A significant improvement from 1.2 — but not the destination. We are still working to bring it lower. His oxidised LDL normalised to 28 U/L. His particle size distribution shifted from predominantly small-dense to large-buoyant. He noticed the difference before his blood work confirmed it — faster recovery after long-haul travel, sustained clarity through back-to-back decision sessions, and a stability in afternoon energy he had written off as age-related years earlier.

This is the difference between screening for disease and engineering for performance. Standard lipid panels tell you whether you currently have cardiovascular pathology. Particle counting tells you what your risk trajectory looks like over the next two decades of high-output living.

Optimise today for tomorrow.